pneumocysti
pneumonia
pcp
pulmonari
infect
caus
pneumocysti
jirovecii
remain
one
preval
opportunist
infect
immunocompromis
patient
develop
highli
activ
antiretrovir
therapi
effect
prophylaxi
pcp
reduc
mortal
pcp
patient
human
immunodefici
viru
hiv
howev
number
patient
receiv
immunosuppress
therapi
organ
transplant
antitumor
chemotherapi
increas
incid
pcp
hivneg
patient
also
increas
typic
hivposit
patient
follow
insidi
cours
contrast
hivneg
patient
pcp
present
abruptonset
hypoxem
respiratori
failur
therefor
necessari
treat
infect
complic
respiratori
failur
aris
howev
earli
treatment
sometim
difficult
diagnosi
pcp
mostli
clinic
one
critic
care
set
past
sever
decad
trimethoprimsulfamethoxazol
tmpsmx
remain
drug
choic
pcp
high
mortal
rate
hivneg
patient
suggest
antipcp
treatment
start
empir
patient
suspect
moder
sever
pcp
howev
tmpsmx
induc
sever
side
effect
includ
granulocytopenia
skin
erupt
hepatotox
renal
toxic
use
tmpsmx
inappropri
also
allow
resist
strain
develop
lot
literatur
regard
pcp
hivneg
patient
howev
previou
studi
focus
patient
factor
laboratori
find
associ
clinic
outcom
investig
delay
initi
antipcp
treatment
therapi
hivneg
patient
compar
hivposit
patient
prior
studi
evalu
effect
earli
antipcp
treatment
clinic
outcom
hivneg
patient
sever
pcp
therefor
studi
investig
associ
time
antipcp
treatment
clinic
outcom
hivneg
patient
pcp
present
hypoxem
respiratori
failur
consecut
patient
older
year
admit
medic
icu
emerg
depart
ed
acut
respiratori
failur
screen
inclus
fig
clinic
data
patient
enrol
also
includ
previou
studi
patient
includ
microbiolog
confirm
diagnosi
pcp
requir
respiratori
support
mechan
ventil
includ
noninvas
ventil
highflow
nasal
cannula
respiratori
failur
patient
exclud
posit
hiv
antibodi
test
final
patient
neither
respiratori
symptom
abnorm
find
chest
radiograph
initi
present
exclud
studi
patient
multipl
admiss
acut
respiratori
failur
due
pcp
studi
period
first
icu
admiss
evalu
diagnosi
pcp
base
clinic
symptom
presenc
new
infiltr
chest
radiograph
along
morpholog
identif
organ
bronchoalveolar
lavag
bal
fluid
lung
tissu
obtain
transbronchi
lung
biopsi
tblb
bal
fluid
sampl
stain
use
gram
ziehlneelsen
method
cultur
bacteria
mycobacteria
fungi
multiplex
nest
polymeras
chain
reaction
pcr
assay
use
detect
follow
influenza
virus
b
parainfluenza
virus
respiratori
syncyti
viru
adenoviru
quantit
realtim
pcr
use
measur
cytomegaloviru
cmv
deoxyribonucl
acid
dna
bal
fluid
microbiolog
identif
pjirovecii
confirm
document
organ
wright
giemsa
gramweigert
stain
cyst
gomori
methenamin
silver
calcofluor
white
stain
follow
data
extract
medic
record
gener
demograph
inform
underli
diseas
medic
use
previou
month
pcp
prophylaxi
need
renal
replac
therapi
need
vasopressor
support
antipcp
medic
newli
develop
organ
failur
icu
stay
also
collect
follow
laboratori
data
medic
record
white
blood
cell
count
absolut
neutrophil
count
absolut
lymphocyt
count
albumin
creactiv
protein
arteri
partial
pressur
oxygen
fraction
inspir
oxygen
ratio
pf
ratio
alveolararteri
oxygen
gradient
aa
sever
ill
assess
use
simplifi
acut
physiolog
score
sap
sequenti
organ
failur
assess
sofa
score
final
studi
clinic
outcom
includ
length
icu
stay
length
hospit
stay
icu
inhospit
mortal
time
antipcp
treatment
interv
defin
number
hour
time
emerg
room
arriv
initi
administr
antipneumocysti
antibiot
classifi
patient
two
group
accord
time
initi
antipcp
treatment
microbiolog
diagnosi
earli
empir
treatment
group
definit
treatment
group
dose
corticosteroid
use
immunosuppress
adjunct
therapi
pcp
express
prednisoloneequival
dose
adjunct
corticosteroid
therapi
defin
start
within
h
initi
specif
antipcp
treatment
consist
least
mg
prednison
twice
daili
day
regardless
subsequ
taper
schedul
use
corticosteroid
onset
pcp
failur
antipcp
treatment
defin
follow
progress
clinic
deterior
demonstr
inabl
maintain
stabl
despit
increas
progress
deterior
vital
sign
increas
requir
despit
day
appropri
therapi
breakthrough
pcp
infect
defin
diagnos
patient
receiv
prophylact
agent
known
activ
p
jirovecii
least
day
prior
diagnosi
data
present
median
interquartil
rang
iqr
continu
variabl
number
percentag
categor
variabl
continu
variabl
analyz
use
mannwhitneywilcoxon
u
test
categor
variabl
analyz
use
pearson
test
fisher
exact
test
trend
test
use
examin
trend
hospit
mortal
rate
across
time
quartil
antipcp
treatment
adjust
potenti
confoud
factor
associ
time
antipcp
treatment
inhospit
mortal
multipl
logist
regress
analysi
use
final
compar
baselin
characterist
clinic
outcom
earli
empir
treatment
group
definit
treatment
group
probabl
surviv
antipcp
treatment
group
estim
kaplanmei
method
compar
logrank
test
variabl
pvalu
less
univari
analys
well
priori
variabl
age
sex
enter
multipl
logist
regress
model
inhospit
mortal
outcom
variabl
interest
reduc
risk
multicollinear
one
close
correl
variabl
candid
inclus
final
model
data
present
adjust
odd
ratio
confid
interv
ci
test
twosid
p
valu
consid
statist
signific
analys
perform
use
spss
window
ver
ibm
corp
armonk
ny
usa
studi
period
total
patient
pcp
admit
icu
respiratori
support
nineteen
patient
exclud
studi
hiv
infect
exclud
patient
initi
admit
gener
ward
outpati
care
caus
n
transfer
hospit
n
initi
chief
complaint
unrel
respiratori
symptom
n
patient
acut
hypoxem
respiratori
failur
new
infiltr
chest
radiograph
includ
patient
baselin
characterist
summar
tabl
median
patient
age
iqr
year
thirtyf
patient
men
main
underli
condit
associ
develop
pcp
includ
malign
n
histori
solid
organ
transplant
n
patient
immunosuppress
develop
pcp
twentytwo
patient
receiv
system
steroid
median
prednisoloneequival
dose
mgday
patient
receiv
system
steroid
two
patient
histori
receiv
prophylact
tmpsmz
time
icu
admiss
patient
hypoxemia
requir
mechan
ventil
n
highflow
nasal
cannula
support
n
median
pf
ratio
mmhg
aa
mmhg
twelv
patient
requir
vasopressor
support
one
need
renal
replac
therapi
median
sap
sofa
score
icu
admiss
respect
patient
underw
bronchoscopi
bal
tblb
within
hour
er
visit
tabl
diagnosi
pcp
base
microbiolog
identif
p
jirovecii
bal
fluid
n
lung
biopsi
specimen
n
seven
patient
posit
p
jirovecii
bal
fluid
patholog
specimen
addit
p
jirovecii
pathogen
simultan
isol
respiratori
specimen
time
diagnosi
common
simultan
isol
pathogen
cmv
patient
bacteria
virus
cmv
patient
treat
appropri
antipcp
treatment
primarili
involv
tmp
mgkgday
smz
mgkgday
thirtyon
patient
treat
tmpsmz
empir
prior
confirm
microbiolog
diagnosi
median
time
antipcp
treatment
hour
baselin
characterist
hospit
mortal
rate
accord
time
antipcp
treatment
quartil
present
addit
file
tabl
fig
respect
interestingli
hospit
mortal
rate
associ
increas
quartil
time
antipcp
treatment
p
test
trend
patient
except
one
treat
adjunct
corticosteroid
one
patient
advers
reaction
tmpsmz
involv
electrolyt
imbal
day
use
exclud
patient
initi
treatment
respons
assess
day
patient
respond
initi
treatment
tmpsmz
patient
subsequ
treat
clindamycinprimaquin
n
pentamidin
n
salvag
therapi
pcp
icu
stay
organ
failur
newli
develop
patient
includ
shock
requir
vasopressor
patient
acut
kidney
injuri
requir
renal
replac
therapi
tabl
icu
mortal
median
stay
day
ultim
patient
die
hospit
median
hospit
stay
day
earli
empir
treatment
group
contain
patient
definit
treatment
group
contain
patient
signific
differ
baselin
characterist
diagnosi
treatment
pcp
except
median
time
antipcp
treatment
h
earli
empir
treatment
group
vs
h
definit
treatment
group
p
addit
file
tabl
addit
file
tabl
comparison
clinic
outcom
two
group
signific
differ
mortal
length
stay
tabl
addit
earli
empir
treatment
significantli
affect
overal
surviv
fig
although
probabl
surviv
earli
empir
treatment
group
appear
increas
first
week
antipcp
treatment
differ
statist
signific
p
logrank
test
univari
comparison
clinic
characterist
hospit
survivor
nonsurvivor
present
tabl
compar
survivor
nonsurvivor
like
older
vs
p
requir
mechan
ventil
vs
p
sap
score
increas
vs
p
cmv
coinfect
vs
p
fail
initi
antipcp
treatment
vs
p
adjust
potenti
confound
factor
age
adjust
ci
p
failur
initi
treatment
adjust
ci
p
independ
associ
increas
mortal
tabl
howev
time
antipcp
treatment
associ
increas
mortal
studi
investig
associ
time
antipcp
treatment
clinic
outcom
hivneg
patient
pcp
present
hypoxem
respiratori
failur
result
suggest
clinic
outcom
hivneg
patient
pcp
respiratori
failur
unrel
time
initi
antipcp
treatment
addit
clinic
outcom
patient
receiv
earli
empir
treatment
better
patient
receiv
definit
treatment
microbiolog
diagnosi
last
decad
substanti
declin
pcprelat
mortal
among
hivposit
patient
increas
mortal
pcp
hivneg
patient
delay
therapi
hivneg
patient
compar
hivposit
patient
associ
higher
mortal
find
suggest
empir
therapi
pcp
initi
patient
high
clinic
suspicion
pcp
unfortun
clinic
tool
rapidli
identifi
patient
risk
pcp
empir
treatment
warrant
addit
preval
pcp
hivneg
cancer
patient
acut
respiratori
failur
diffus
pulmonari
infiltr
empir
therapi
pcp
patient
therefor
would
unnecessari
potenti
caus
harm
although
sever
prior
studi
found
delay
therapi
antipcp
treatment
associ
higher
mortal
found
differ
difficult
explain
discrep
may
due
differ
unit
use
measur
delay
treatment
hour
vs
day
unlik
previou
studi
measur
time
antipcp
treatment
calcul
hour
instead
day
anoth
potenti
explan
conflict
result
differ
studi
popul
includ
hivneg
patient
analysi
associ
time
antipcp
treatment
mortal
addit
major
patient
requir
mechan
ventil
admiss
result
suggest
empir
treatment
pcp
hivneg
patient
present
hypoxem
respiratori
failur
given
variou
potenti
harm
side
effect
treatment
pcp
hivneg
patient
caus
acut
fulmin
pneumonia
abruptonset
respiratori
failur
need
mechan
ventil
observ
high
mortal
rate
patient
requir
mechan
ventil
consist
find
previou
report
addit
sever
ill
time
icu
admiss
associ
higher
mortal
find
suggest
patient
gener
condit
underli
diseas
associ
pcp
import
earli
initi
antipcp
treatment
hivneg
patient
given
high
efficaci
bioavailavil
tmpsmz
use
firstlin
agent
treatment
pcp
patient
without
hiv
infect
despit
treatment
failur
report
tmpsmz
patient
although
larg
random
trial
shown
efficaci
tmpsmz
hivposit
patient
small
observ
studi
demonstr
hivneg
patient
therefor
futur
studi
must
evalu
potenti
associ
failur
initi
treatment
tmpsmx
increas
mortal
hivneg
patient
howev
might
difficult
distinguish
reason
clinic
deterior
includ
progress
diseas
advers
fail
treatment
effect
concomit
infect
studi
patient
initi
treat
tmpsmz
failur
initi
antimicrobi
treatment
pcp
significantli
associ
increas
mortal
adjust
potenti
confound
factor
failur
initi
antimicrobi
treatment
still
significantli
associ
increas
mortal
case
treatment
failur
howev
like
caus
mortal
diseas
sever
diagnosi
treatment
rather
drug
resist
regardless
futur
studi
need
substanti
find
patient
sever
potenti
limit
studi
acknowledg
first
given
retrospect
observ
design
studi
may
subject
select
bia
addit
studi
conduct
singl
center
special
icu
larg
number
cancer
patient
receiv
chemotherapi
therefor
find
may
readili
generaliz
institut
patient
popul
final
could
compar
result
hivposit
patient
sinc
number
hivposit
patient
diagnos
pcp
small
compar
studi
period
howev
patient
hematolog
malign
solid
tumor
receiv
chemotherapi
higher
risk
pcp
compar
hivneg
patient
therefor
result
repres
actual
practic
treatment
pcp
hivneg
patient
conclus
data
suggest
relationship
time
antipcp
treatment
treatment
outcom
hivneg
patient
pcp
associ
hypox
respiratori
failur
